UF links PIK3CA mutations to immune disruption in canine HSA: full analysis

A University of Florida research team says it has identified a key genetic-immune connection in canine hemangiosarcoma, one of the deadliest cancers seen in dogs. In findings highlighted by UF on January 21, 2025, the group reported that activating mutations in PIK3CA help drive immune signaling changes that may allow tumor cells to manipulate nearby healthy cells and create a more permissive environment for cancer growth. UF framed the work as a potential step toward better therapies for both dogs with hemangiosarcoma and people with the related, much rarer cancer angiosarcoma. (vetmed.ufl.edu)

The background matters here. Canine hemangiosarcoma is common enough to be a meaningful clinical burden in small animal practice, but still frustratingly difficult to catch before crisis presentation. UF notes that tumors can grow silently before rupturing, and that long-term survival remains poor. That clinical reality is one reason comparative oncology researchers keep returning to hemangiosarcoma: the canine disease shares histologic and genomic features with human angiosarcoma, while occurring often enough in dogs to support deeper biologic and translational study. Earlier comparative genomics work found recurrent mutations in TP53 and PIK3CA, helping establish hemangiosarcoma as a relevant model for vascular sarcoma biology across species. (vetmed.ufl.edu)

The new work appears to extend that foundation from mutation cataloging into mechanism. According to UF and the associated Cancer Gene Therapy publication, the researchers used engineered hemangiosarcoma models carrying the PIK3CA H1047R hotspot mutation and found that mutant cells developed distinct transcriptional and chromatin-accessibility programs enriched for immune cytokine signaling, including IL-6, IL-8, and MCP-1. UF’s summary says the team also observed that hemangiosarcoma cells can hijack nearby healthy cells to help build tumor-supporting vasculature and stimulate blood cell production in ways that may favor “cancer-friendly” immune populations. Taken together, the picture is less about tumor growth alone and more about active remodeling of the tumor immune niche. (vetmed.ufl.edu)

This isn’t happening in a vacuum. Prior work has already suggested that PIK3CA is a clinically relevant target in canine hemangiosarcoma. Earlier laboratory studies found anti-tumor activity from the PI3K inhibitor alpelisib in PIK3CA-mutant canine hemangiosarcoma cell lines, and a 2025 Scientific Reports analysis of real-world clinico-genomic data reported that PIK3CA mutation predicted response to treatment plans that included targeted therapy, with signal for benefit from mTOR inhibition in particular. That doesn’t make the pathway ready for routine frontline use in general practice, but it does strengthen the case for mutation-informed treatment planning in oncology settings that have access to sequencing and targeted agents. (pmc.ncbi.nlm.nih.gov)

Expert reaction in the public record has been measured but notable. UF quoted lead researcher Jon Kim, DVM, PhD, saying the findings offer “critical insights” that could support novel therapies for dogs with PIK3CA-mutant hemangiosarcoma as well as human angiosarcoma patients. The AKC Canine Health Foundation also lists related funded work from Kim’s group on “reprogramming the tumor immune niche,” suggesting this line of investigation has been building over multiple years rather than emerging as a one-off observation. (vetmed.ufl.edu)

Why it matters: For veterinary professionals, the practical takeaway is that hemangiosarcoma may be moving, slowly, from a disease managed primarily by anatomic site and stage toward one that can also be stratified by molecular biology. If PIK3CA mutation status helps identify tumors with distinct immune behavior and distinct therapeutic vulnerabilities, that could influence how oncologists think about sequencing, prognostic conversations, referral decisions, and clinical trial design. It also reinforces the broader relevance of canine oncology research: because human angiosarcoma is so rare, naturally occurring disease in dogs may continue to generate evidence that is difficult to obtain in human-only studies. (vetmed.ufl.edu)

There are still important limits. The mechanistic findings are compelling, but they don’t yet establish a new standard of care. Much of the current evidence remains preclinical or retrospective, and the field still needs prospective validation showing whether mutation-guided therapy improves outcomes in a reproducible way. Veterinary teams should also be cautious not to overextend the translational promise: comparative relevance to human angiosarcoma is real, but translation from model system to approved therapy is rarely straightforward. (nature.com)

What to watch: The next milestones will likely be prospective clinical studies in dogs, broader use of genomic profiling in hemangiosarcoma cases, and combination strategies that test whether disrupting PIK3CA-driven signaling plus the downstream immune microenvironment can improve survival beyond what surgery and conventional chemotherapy have delivered so far. (nature.com)